Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Clinical trial NCT07502768 · RECRUITING
Trial details
- NCT number
- NCT07502768
- Sponsor
- Rong Tao
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-30
- Primary completion
- 2027-12-30
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.